United States · FDA National Drug Code directory
Creon
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0032-0045_a43ddd93-7d01-4bb9-95e3-b0629fe8ac87
- Product NDC
- 0032-0045
- Form
- CAPSULE, DELAYED RELEASE
- Composition / generic term
- Pancrelipase
- Labeler
- AbbVie Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20231012
- Source listing expiry
- 20271231
Source-listed ingredients
- PANCRELIPASE AMYLASE — 15000 [USP'U]/1
- PANCRELIPASE LIPASE — 3000 [USP'U]/1
- PANCRELIPASE PROTEASE — 9500 [USP'U]/1
These values do not establish equivalence or a dose recommendation.
Packages
- 70 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0032-0045-30) · 0032-0045-30
- 70 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0032-0045-70) · 0032-0045-70
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →